High-quality remission: potential benefits of the melatonergic approach for patients with major depressive disorder
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Full remission of symptoms is the goal for the acute treatment of depression, because incomplete remission is associated with poor outcomes including higher risk of relapse and chronicity. The current definitions for remission (e.g. a score of </=7 on the Hamilton Depression Rating Scale), however, allow for the presence of residual symptoms of depression even if remission is attained. The focus now is on the quality of remission, that is, ensuring a minimum of such residual symptoms, because the consequences of low-quality remission also include impairment in psychosocial functioning. The most common residual symptoms are sleep disturbances, fatigue, and disinterest. Sleep-associated residual symptoms are particularly common, and are a major concern because most current treatments fail to adequately address sleep disturbances and may even aggravate them. Other side effects of current treatments, such as weight gain and sexual dysfunction, may also reduce the quality of remission. A novel approach to the treatment of depression with agomelatine, a melatonergic MT1 and MT2 receptor agonist and 5-HT2C receptor antagonist, may be an effective treatment that improves the quality of remission, as it combines good efficacy with positive effects on sleep, neutral effects on sexual function, and a favorable side effect profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Frank, E. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810330075011 · Cited by 1,959 · cited 3×
“Quantifying remission Consensus definitions for clinical response and remission were first produced in the early 1990s at a meeting of the MacArthur Foundation Task Force (Frank et al., 1991).”
BackgroundMethodBupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945 · cited 2×
“A systematic review of 31 randomized trials including 4410 participants demonstrated that continuing antidepressant treatment reduced the risk of relapse by 70% (Geddes et al., 2003).”
BackgroundResultResidual symptoms after partial remission: an important outcome in depression
Paykel, E. S., Ramana, R., Cooper, Z., Hayhurst, H., Kerr, J., & Barocka, A. (1995) · Psychological Medicine · doi:10.1017/s0033291700033146 · Cited by 791 · cited 2×
“still with a HAMD score Z 8) had a much higher relapse rate (76%) than the group of patients with full remission (25%) (Paykel et al., 1995).”
BackgroundJudd, L. L., Akiskal, H. S., Maser, J. D., Zeller, P. J., Endicott, J., Coryell, W., Paulus, M. P., Kunovac, J. L., Leon, A. C., Mueller, T. I., et al. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.8.694 · Cited by 775
Fava, M., McCall, W. V., Krystal, A., Wessel, T., Rubens, R., Caron, J., Amato, D., & Roth, T. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.01.016 · Cited by 480 · cited 2×
“The relief of antidepressantinduced insomnia may also improve rates of response and remission, as demonstrated in a placebo-controlled study in 545 patients with MDD treated with the SSRI fluoxetine, with or without nightly administration of the nonbenzodiazepine hypnotic eszopiclone (Fava et al., 2006).”
BackgroundResidual symptoms in depressed patients who respond acutely to fluoxetine
Nierenberg, A. A., Keefe, B. R., Leslie, V. C., Alpert, J. E., Pava, J. A., Worthington, J. J., Rosenbaum, J. F., & Fava, M. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0403 · Cited by 470 · cited 2×
“One study reported that residual symptoms were still present in 80% of remitted patients after treatment with fluoxetine (Nierenberg et al., 1999).”
BackgroundRecent developments and current controversies in depression
Ebmeier, K. P., Donaghey, C., & Steele, J. D. (2006) · The Lancet · doi:10.1016/s0140-6736(06)67964-6 · Cited by 434 · cited 2×
“Major depressive disorder (MDD) is an extremely disabling medical condition involving significant functional impairment and an increased risk of mortality, particularly that due to suicide (Ebmeier et al., 2006).”
BackgroundAntidepressants and Sleep: A Qualitative Review of the Literature
Wilson, S., & Argyropoulos, S. (2005) · Drugs · doi:10.2165/00003495-200565070-00003 · Cited by 392
Cited by
Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis
Green, M. J., Matheson, S. L., Shepherd, A., Weickert, C. S., & Carr, V. J. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.88 · Cited by 453
Drexhage, R. C., Knijff, E. M., Padmos, R. C., Heul-Nieuwenhuijzen, L. V. D., Beumer, W., Versnel, M. A., & Drexhage, H. A. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.144 · Cited by 263
Miodownik, C., Maayan, R., Ratner, Y., Lerner, V., Pintov, L., Mar, M., Weizman, A., & Ritsner, M. S. (2011) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e318220d8c6 · Cited by 31
Kudlek Mikulic, S., Mihaljevic-Peles, A., Sagud, M., Bajs Janovic, M., Ganoci, L., Grubisin, J., Kuzman Rojnic, M., Vuksan Cusa, B., Bradaš, Z., & Božina, N. (2017) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2017.1340518 · Cited by 25
Metadata
- Authors
- Lam, R. W.
- Venue
- International Clinical Psychopharmacology
- Published
- 2007-10
- Volume
- 22
- Issue
- Supplement 2
- Pages
- S21-S25
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W1992547531
- Cited by
- 30
- References
- 15
- FWCI
- 3.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High-quality remission: potential benefits of the melatonergic approach for patients with major depressive disorder. https://app.cochat.ai/papers/10.1097/01.yic.0000277959.60604.d1
- The paper
- Lam, R. W. (2007). High-quality remission: potential benefits of the melatonergic approach for patients with major depressive disorder. International Clinical Psychopharmacology. https://doi.org/10.1097/01.yic.0000277959.60604.d1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.